Blood cancer discoveryJournal Article
05 May 2025
SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.
N. Puig reports personal fees from Amgen, Bristol Myers Squibb, Takeda, The Binding Site, Sanofi, and Menarini and grants from Pfizer outside the submitted work. M.-T. Cedena reports personal fees from Johnson&Johnson and Sobi outside the submitted work. A. Oriol reports personal fees from Sanofi, Pfizer, Amgen, GlaxoSmithKline, Bristol Myers Squibb, Johnson&Johnson, and Oncopeptides outside the submitted work. L. Rosinol reports other support from Janssen, Bristol Myers Squibb, Sanofi, Takeda, GlaxoSmithKline, Menarini Stemline, and Pfizer outside the submitted work. F. de Arriba reports personal fees and nonfinancial support from Janssen-Cilag, Bristol Myers Squibb/Celgene, Amgen, GlaxoSmithKline, and Sanofi outside the submitted work. V. Cabañas reports grants and personal fees from Johnson&Johnson and personal fees from Bristol Myers Squibb, Amgen, Biogene, GlaxoSmithKline, Menarini, and Sanofi outside the submitted work. M.-V. Mateos reports personal fees from Johnson&Johnson, Bristol Myers Squibb, GlaxoSmithKline, Sanofi, Pfizer, Kite, Stemline, Oncopeptides, AbbVie, and Roche outside the submitted work. J.F. San-Miguel reports other support from Abbvie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, and SecuraBio outside the submitted work. B. Paiva reports personal fees from Adaptive, Amgen, and Becton Dickinson, grants and personal fees from Sanofi, Takeda, Bristol Myers Squibb–Celgene, and Janssen, and personal fees from Merck, Novartis, and Roche outside the submitted work. No disclosures were reported by the other authors.
More resources:
Share: